1



================================================================================


                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                   ----------


                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


                                   ----------


               Date of Report (Date of earliest event reported):


                               SEPTEMBER 16, 1997



                          CAMBRIDGE NEUROSCIENCE, INC.
                          ----------------------------
             (Exact name of registrant as specified in its charter)


  DELAWARE                       0-19193                       13-3319074
  --------                       -------                       ----------
(State or other                (Commission                    (IRS Employer  
jurisdiction of                File Number)                 Identification No.) 
incorporation)


              ONE KENDALL SQUARE, BUILDING 700, CAMBRIDGE, MA 02139
              -----------------------------------------------------
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (617) 225-0600
                                                            -------------


                            Total Number of Pages 6.
                            Exhibit Index at Page 4.

================================================================================


   2
Item 5 - Other Events
- ---------------------

     On September 16, 1997, Cambridge NeuroScience, Inc. (the "Company") issued
a news release announcing the discontinuation of the Phase III trial of
CERESTAT(1) for traumatic brain injury. The information contained in this news
release is incorporated herein by reference and filed as Exhibit 99.5 hereto.

Item 7 - Financial Statements and Exhibits
- ------------------------------------------

     (c)  Exhibits.

          99.5     The Company's News Release dated September 16, 1997.




- -----------------------
(1)   CERESTAT is a registered trademark of Boehringer Ingelheim International 
      GmbH.





                                       2
   3

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                      CAMBRIDGE NEUROSCIENCE, INC.



Date:  September 16, 1997             /s/ Harry W. Wilcox, III
                                      ----------------------------------------
                                      Harry W. Wilcox, III
                                      Sr. Vice President, Finance and Business
                                      Development; Chief Financial Officer







                                       3
   4

                                  EXHIBIT INDEX
                                  -------------



Exhibit
Sequential
Number                     Description
- ----------                 -----------

99.5                       The Company's News Release dated September 16, 1997.





                                       4